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HSV Herpes simplex virus 
HSV-1 Herpes simplex virus type 1 
HSV-2                 Herpes simplex virus type 2 
VZV Varicella zoster virus 
HCMV Human cytomegalovirus 
HHV-6 Human herpes virus 6 
HHV-7 Human herpes virus 7 
EBV Epstein-Barr virus 
Nm Nanometers 
DNA Deoxyribonucleic acid 
mRNA Messenger ribonucleic acid  
g Before a capital letter, glycoprotein B – N (gB - gN) 
kbp kilo base pair 
UL Long unique sequence of HSV genome  
US Short unique sequence of HSV genome  
TRS / L Terminal repeat sequences flanking US or UL   
Vhs Virus-host shut-off protein 
VP16                     Virion protein 16 
HveA Herpes virus entry protein A 
TNF Tumor necrosis factor 
Prr1/2 Poliovirus receptor-related proteins-1 or 2 
HveB Herpes virus entry protein B 
HveC Herpes virus entry protein C 
MtrI Morphological transforming region of HSV-1 
mtrII / mtrIII Morphological transforming regions of HSV-2 
RRI Ribonucleotide reductase 
HPV Human papillomavirus 
WB Western blot 
ELISA Enzyme linked-immunosorbent assay 
PCR Polymerase chain reaction 
HCV Hepatitis C virus 
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HIV Human immunodeficiency virus 
GUD Genital ulcer disease 
STD Sexually transmitted disease 



























1.0 Herpes simplex virus – General aspects 
1.1 Taxonomy 
 
Herpes simplex viruses (HSV) are important human pathogens causing diseases in a variety 
of different tissues and animal species. There are two antigenic types, HSV-1 and HSV-2, 
with HSV-1 being most often transmitted non-sexually and HSV-2 most usually sexually 
transmitted (Umene and Kawana, 2000; 2003). HSV belongs to the family Herpesviridae. 
The family is divided into three subfamilies; α (alpha), β (beta) and γ (gamma) herpesviruses, 
based on biological properties. At present nine herpesviruses are recognized as natural human 
pathogens (Roizman and Pellet, 2001). Herpes simplex virus types 1 and 2 (HSV-1 and HSV-
2) and Varicella-zoster virus (VZV) belong to the alphaherpesviruses (alphaherpesvirinae), 
which have a wide host range, a relatively short life cycle and establish latent infections 
preferentially in sensory ganglia. Human cytomegalovirus (HCMV), and human herpes 
viruses 6A, 6B and 7 (HHV-6A, HHV-6B and HHV-7) belong to betaherpesviruses 
(betaherpesvirinae), which have a restricted host range and multiplication of the viruses 
appears to be slow. These viruses establish latency in lymphoreticular cells. Finally Epstein-
Barr virus (EBV) and human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) are B 
lymphotropic virus belonging to the gammaherpesviruses (gammaherpesvirinae), and latency 




Studies have shown that all herpes virions consist of four elements: DNA core, capsid, 
tegument and glycoprotein-containing envelope (Roizman and Pellet, 2001). A schematic 
presentation is given in Figure 1. The HSV genome contains approximately 152-kbp (Rajcani 
et al., 2004). The DNA of HSV-1 and HSV-2 consist of two covalently linked segments 
called the L (long) and S (short), with unique sequences-UL (unique long) and US (unique 
short), flanked by large inverted repeat sequences which are designated terminal and internal 
repeats of the long (TRL and IRL) and short (TRS and IRS) unique sequences, respectively 
(Rajcani et al., 2004). Additionally, the unique L and S components can invert relative to one 
another, yielding four linear isomers, and each of the four is equally virulent (functionally 
equivalent) in the host cell (Roizman and Knipe, 2001; Whitley and Roizman, 2001; 
Kimberlin, 2004). The genes of the long and short unique sequences are designated UL1 to 






Fig.1. Schematic diagram of the HSV-1 virion (from Haarr and Skulstad, 1994) 
 
The capsid is a structurally well-defined icosahedron, an important function of which is to 
contain and protect the viral genome. It is 125 nm in diameter and approximately 15 nm thick, 
and it is organized into 162 capsomers, of which 150 are hexavelent capsomers (hexons), and 
12 pentavalent capsomers (pentons) (Trus et al., 2001; Mettenleiter, 2002). All capsomers are 
connected in groups of three by trigonal nodules or triplexes on the capsid surfaces 
(Newcomb et al., 2003; 2005; Singer et al., 2005). Three types of capsids are reported 
(Warner et al., 2000; Desai, 2000). The C capsid are mature forms and contain viral DNA. 
The B capsids do not contain DNA, but do contain the scaffold proteins and are believed to be 
an early stage of viral assembly. The A capsids are empty. These are thought to be capsids 
that failed in the packaging process. In cell free system a fourth form of capsids has been 
identified, termed procapsid and this may be a precursor of these three capsids (Newcomb et 
al., 2000; Chi and Wilson, 2000; Sheaffer et al., 2000).  
 
The tegument is the least understood component of the virion in relation to its structure and 
function, its role in virus entry, and mechanisms of its assembly and incorporation into 
virions. However, cryoelectron micoroscope analyses showed that at least the innermost part 
of the tegument that is located adjacent to the capsid may also exhibit icosahedral symmetry 
(Zhou et al., 1999). The tegument contains at least 19 different HSV proteins (Mettenleiter, 
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2002; Miranda-Saksena et al., 2002). While the precise functions of most of the individual 
tegument proteins are not yet clear, it seems likely that they perform dual roles in the virus 
replication cycle, providing activities both at the onset of infection, as the capsid-tegument 
enters the cell, and during virion assembly, as virus matures and exits the cell. UL 31 and UL 
34 tegument proteins form a complex which plays an important role in envelopment of 
nucleocapsids (Reynolds et al., 2001). UL 41 has been implicated in virally induced host-cell 
shut off by degradation of host mRNAs soon after infection (Whitley and Roizman, 2001; 
Mettenleiter, 2004). The UL48 protein is the α-transinducing factor, αTIF, responsible for the 
trans-activation of immediate early genes (Mettenleiter, 2004). It is also reported that UL48 
plays a direct role in virion assembly and egress (Mossman et al., 2000). The UL 46 and UL 
47 proteins modulate the activity of the αTIF protein (Donnelly and Elliott, 2001, 2001; Kopp 
et al., 2002). The UL6, UL15, UL17, UL25, UL28, UL32, and UL33 proteins are required for 
cleavage and packaging of viral DNA (White et al., 2003).  
 
On the outer side of the tegument is the envelope, which is a lipid bilayer derived from the 
host cell. HSV specifies at least 12 glycoproteins designated gB, gC, gD, gE, gG, gH, gI, gK, 
gL, gM and gJ and gN (Whitley and Roizman, 2001; Foster et al., 2001). These glycoproteins 
function in several important roles, including pH-independent virus entry via fusion of the 
virion envelope with cellular membranes (Milne et al., 2005), egress of infectious virion 
particles (Foster et al., 2001, 2003; Neubauer and Osterrieder, 2004; Melancon et al., 2005), 
cell-to-cell spread (Rauch et al., 2000; Johnson et al., 2001), virus induced cell fusion (Bender 
et al., 2005) and immune evasion (Trybala E., 2000; Saldanha et al., 2000; Rux et al., 2002). 
Antigenic specificity is provided by gG, with the resulting antibody response allowing for the 
distinction between HSV-1 (gG-1) and HSV-2 (gG-2) (Eriksson et al., 2004).  
  
1.3 Regulation of gene expression 
 
During productive infections, transcription of the viral genome occurs in a cascade-like 
fashion resulting in immediate-early, early, and late viral mRNAs. The α (immediate-early) 
genes, require no prior viral protein synthesis for their expression and are responsible for the 
expression of the other genes in a regulated way. β (early) genes, whose expression is totally 
independent of viral DNA, encode proteins and enzymes which are directly involved in DNA 
synthesis and nucleotide metabolism. The beta (β) genes induce the activation of the last 
group of genes, the gamma (γ) or late genes, coding for many of the structural proteins in the 
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HSV virion, including capsid proteins, which are translated in the cytoplasm and then 
imported into the nucleus where capsid assembly occurs (Mettenleiter, 2004).  
 
1.4 Entry of HSV into host cells 
 
The entry of HSV requires binding of virus to receptors on the cell surface and fusion of the 
virion envelope with the cell plasma membrane (Spear et al., 2000; Spear and Longnecker, 
2003). The initial attachment is mediated through viral glycoprotein C (gC) and/or gB to cell 
surface heparan sulfate proteoglycans (Langeland et al., 1990; Sakisaka et al., 2001; 
Cheshenko and Herold, 2002). The fusion of the viral envelope with the plasma membrane 
requires gB, gD, gH, and gL (Muggeridge, 2000; Pertel et al., 2001; Avitabile et al., 2003). 
Three cell surface receptors for HSV have been identified: herpes virus entry mediator A 
(HveA or HVEM) is a member of the tumor necrosis factor receptor (TNFR) family. The 
other two receptors are HveB and HveC (Lopez et al., 2000; Connolly et al., 2001; Terry-
Allison et al., 2001; Krummenacher et al., 2004; Jogger et al., 2004).  It is also reported that 
HveC allows viral entry by directly interacting with gD, as shown for HveA (Connolly et al., 
2001; Milne et al., 2001; Whitbeck et al., 2001). Recently both HveB and HveC were found 
to be components of a novel cell-cell adhesion system, and to belong to the Ig superfamily. 
They were therefore renamed as nectin-1 and nectin-2, respectively (Lopes et al 2000; Satoh-
Horikawa et al., 2000; Takahashi et al, 2001).  
 
1.5 Life cycle of HSV 
 
HSV replicates by three rounds of transcription that yields: immediate-early (α) proteins that 
mainly regulate viral replication; early (β) proteins that synthesis and package DNA; and late 















Fig. 3. Diagrammatic representation of the herpesvirus replication cycle (Metteinletter, 2004). 
 
1.6 HSV infections 
 
HSV is a natural pathogens for humans, with particular affinity for the nervous tissue. The 
virus spread from person to person by infected secretions, classically oral secretions for HSV-
1 and genital secretions for HSV-2. There are three types of herpetic infections: lytic 
infection, latent infection and transforming infection. 
 
In a lytic infection, virus multiply inside the nucleus of infected cell. This is followed by 
production of infectious virions before lysis of infected cells, partly due to suppression of host 
protein synthesis by a structural protein named virus host shutoff (vhs) protein, encoded by 
the UL41 gene (Whitley and Roizman, 2001; Mettenleiter, 2004).  
 
In latent infection, viral DNA is maintained in a non-replicative state and persists in the 
nucleus as an episome for the entire life of the individual (Roizman and Knipe, 2001). Virus 
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may reactivate following a variety of local or systemic stimuli to cause recurrent disease 
(Sawtell and Thompson, 2004). During latency, the viral lytic genes are extremely repressed 
and only a single transcription unit encoding the latency-associated transcripts (LATs), 
remain active (Steven et al., 1987; Thompson and Sawtell, 2000; 2001; Peng et al., 2005). 
The most abundant LAT is a 2.0-kb RNA (Rødahl and Haarr, 1997; Inman et al., 2001), 
which is also detected during productive infections (Ahmed et al., 2002). The other LATs are 
1.4- and 1.5-kb long which can only be detected during latency (Kang et al., 2003). The 
molecular mechanisms controlling latency and reactivation remain poorly understood and is a 
focus of active investigation. 
  
The possibility that herpes simplex virus has transforming potential has been a focus of 
interest. Numerous studies have shown that, both HSV-1 and HSV-2 are able to transform the 
morphological phenotype of rodent cells. Transformation by HSV-1 does not require the 
entire viral genome, but is attributed to a region located between map units 0.31 and 0.42 
designated as morphological transforming region of HSV-1 (mtr-I) (Das et al., 1994). Failure 
to detect viral DNA in transformed cells led to the hit-and-run hypothesis of HSV-1 
transformation (McDougall, 2001). Within the HSV-2 genome there are two unique 
morphological transforming regions designated as mtr II and mtr III located between map 
units 0.585 and 0.63 and 0.42 and 0.58 (Jones, 1995). MtrII and mtrIII encompass for the 
large subunit of viral ribonucleotide reductase (RR1) which has transforming potential 
(Aurelius., et al 1998; 1999; Smith et al., 2000). It has been proposed that HSV-2 participates 
as a cofactor in the development of invasive cervical carcinoma (Smith et al., 2002). No 
human tumours has so far been shown to be directly caused by HSV (Lehtinen et al., 2002). 
 
1.7 Human disease 
 
HSV-1 and HSV-2 are common human pathogens that can cause primary and recurrent 
infections of mucous membranes. Primary HSV infections are usually symptomatic but may 
be sub clinical. Recurrent infections are generally less severe than the primary infection. The 
most commonly seen clinical manifestations include oro-facial and genital lesions. Ocular 
infections may include any part of the eye including the retina, conjuctiva, cornea and eyelids 
(Ganatra et al., 2000; Liesegang, 2001; Umene et al., 2003). Meningitis is usually benign, but 
the HSV encephalitis has been associated with high mortality (Tyler et al., 2004). Neonates 
are particularly at risk for serious HSV infections; early treatment appears to be an important 
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determinant of the outcome (Kimberlin et al., 2001; 2001). In addition, immunocompromised 
patients are at risk of developing more severe HSV infections. Cutaneous HSV infections are 
uncommon in healthy persons but may be seen in a number of skin disorders such as eczema 
herpeticum and atopic dermatitis (Wollenberg et al., 2003; Yoshida and Umene, 2003). 
Herpetic whitlow is infection of fingers among dentists and other health care workers (Szinnai 
et al., 2001) whereas infection on bodies of wrestlers is called herpes gladiatorum (Dworkin 
and Shoemaker, 1999). Erythema multiforme is frequently associated with HSV infection 
(Sun et al., 2003; Aurelian et al., 2005; Ono et al., 2005). 
 
1.8 Epidemiology of HSV infection 
 
The prevalence of HSV-2 infection among health adult populations is higher in the USA than 
in Europe. Furthermore, HSV-2 seroprevalence varies widely among European countries 
(Malkin, 2004). In some, but not all countries, HSV-2 seroprevalence appears to be increasing 
(Malkin, 2004). The most recent data available in the United States demonstrate a 30% 
increase of HSV-2 seroprevalence over the past two decades (Malkin, 2004; Bünzli et al., 
2004). The higher HSV-2 seroprevalence has been reported among patients attending sexually 
transmitted disease (STD) clinics (Gottlieb et al., 2002; Weiss, 2004). The situation is not 
well characterized on African content but available data suggest that HSV-2 seroprevalence is 
higher than in the United State (Smith and Robinson, 2000; Weiss, 2004).  
 
HSV is now a major health concern, confirmed by the epidemic of genital HSV and enhanced 
acquisition of human immunodeficiency virus (HIV) infections in association with HSV 
infections (Mbopi-Keou et al., 2002; Celum, 2004). HSV-2 is a common cause of genital 
ulceration (Wawer et al., 1999). In an HIV-negative individual, genital ulcer might increase 
susceptibility to HIV infection by disrupting the mucosal barrier and by inflammatory 
changes, which increase recruitment of HIV target cells to the ulcer (Rottingen et al., 2001). 
 
1.9  Treatment 
 
There is currently no curative therapy of HSV infection. In fact, no drugs are available acting 
on the virus during latency in the dorsal root ganglia. The yet most successful drugs such as 
acyclovir, valacyclovir, famciclovir are all nucleoside analogues inhibiting replication. These 
drugs have similar modes of action. They first undergoes monophosphorylation by virally 
encoded thymidine kinase (TK) and concentrates in infected cells. Host enzymes, cellular 
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kinases further phosphorylate the drug to the active triphosphate form which inhibits viral 
DNA polymerase and consequently viral replication (Chosidow et al., 2001; Tyring et al., 
2002; Coen and Schaffer, 2003). Foscarnet is a pyrophosphate analogue which directly 
inhibits viral DNA polymerase without prior activation by thymidine kinase. In contrast to 
nucleoside analogues, foscarnet is a non-competitive inhibitor of the DNA polymerase (Coen 
and Schaffer, 2003). 
 
Various vaccine against HSV infection have been tested without success, focusing on primary 
prevention and on immunotherapy for those already infected. Continue search for an effective 
vaccine is still on going (Stanberry, 2004; Jones and Cunningham, 2004; Aurelian, 2004; 
Hoshino et al., 2005). 
 
2.0 Diagnosis of HSV infection 
 
Efficient laboratory testing is an essential component for management and development of 
strategies to prevent transmission of HSV infection. Current laboratory methods used to 
diagnose HSV infections include: virus detection, antigen detection, DNA detection and 
serological tests. Virus detection methods through culturing and DNA detection, particularly 
using polymerase chain reaction (PCR), are applicable during active infection in patients 
presenting with lesion. Antigen detection method can be nearly as sensitive as culture 
methods (Ashley and Wald, 1999), and the most sensitive strategy is to perform both tests. 
Serological tests allows identification of silent carriers of HSV infection and provide useful 
information in symptomatic patients when virological tests such as culture, antigen detection 
and PCR are not helpful (Woolley et al., 2000; Ashley, 2001). The application of HSV type-
specific serological tests has been difficult due to strong serological cross-reactivity caused by 
the extensive antigenic similarities between the two viruses (Schmid et al., 1999; Tunbäck et 
al., 2000). The identification of type-specific glycoproteins G-1 (gG-1) and gG-2 in the mid-
1980s seemed to resolve this difficult (Marsden, et al., 1984; Roizman, et al., 1984), because 
it is antigenically distinct for the two viruses. Since the demonstration of two antigenic types, 






3.0 Rationale for the present study 
 
The present study focused on the following four points: 
3.1 Establishment of a new peptide ELISA for detection of HSV-1 antibodies 
 
Problems with the present diagnostic methods: 
Considerable homology exists between HSV-1 and HSV-2 genomes. As a result, most 
polypetides specified by one viral type are antigenically related to polypeptides of the other 
viral type (Schmid et al., 1999; Kimberlin, 2004). One of the consequences is that antibodies 
directed towards antigens from one type of the virus will often cross-react with antigens from 
the other serotype. In addition, tests based on recombinant gG from bacteria or baculovirus 
expression vectors (Parkes, et al., 1991), may not detect all the antibodies elicited in humans 
by exposure to gG, because recombinant gG may lack epitopes that depends upon 
glycosylation mechanisms available in mammalian cells. Therefore, few tests are available to 
date for specific detection of HSV antibodies. The most specific and reliable diagnostic test 
for HSV-1 or HSV-2 specific tests are Western blotting (WB) and Polymerase chain reaction 
(PCR) (Schmid et al., 1999; Madhavan et al., 1999). However, both tests are laborious and /or 
expensive and require expensive equipment and well trained personnel, and are therefore not 
suitable for routine use in clinical laboratory settings.  
 
New possibilities: 
Two new diagnostic approaches have recently been available. Firstly, methods have been 
developed using either the complete glycoprotein gG (gG) or specific epitopes in gG for 
detection of HSV-2 antibodies (Marsden, et al., 1998; Ashley, 2001). The question was if 
epitopes of this glycoprotein in HSV-1 could also be used for detection of HSV-1 specific 
antibodies. Secondly, branched peptides corresponding to the amino acid sequences of certain 
epitopes have been tested and found to be useful for specific detection of antibodies against 
hepatitis C virus (HCV) and HSV-2 (Bhattacherjee, et al., 1995; Marsden, et al., 1998). Here 
we have explored new diagnostic approaches in an attempt to establish a new diagnostic 
method for specific detection of HSV-1 antibodies using branched synthetic oligopeptides 






3.2 Detection of HSV specific antibodies in sera from children and young persons 
 
Most adult people are infected with HSV-1 which is the usual cause of oro-labial herpes, but 
to and increasing extent infections of the genital area. Genital herpes is usually caused by 
HSV-2, and most primary HSV-2 infections do occur later in life. Reports from the African 
continent indicate that the percentage of HSV-2 infected adults has increasing in recent years 
(Weiss, 2004). However, the situation is not well characterized in children and young persons 
in developing countries, although several studies from smaller geographical areas and from 
selected population groups suggest that there is a strong association between HSV-2 
infections and HIV (Nilsen et al., 2005). Here we have analysed sera from Tanzanian children 
and young persons aged 1 – 20 years old in order to determine the acquisition patterns of 
HSV infections. 
 
3.3 Genetic diversity of clinical HSV-2 isolates from Tanzania and Norway 
 
As already mentioned, HSV-2 is the commonest cause of genital ulcer disease. Classically, 
primary infection usually occur later in life. Variations in gG-2 might alter the antibody 
response in the HSV-2 type-specific serological assays based on gG-2 as antigen. This could 
be expressed as a low sensitivity in serotesting of patients harbouring strains carrying one of 
the other gG-2 gene variants if the antigen used as a diagnostic tool is based on the sequence 
of the other genetic variant. So far, the variability of HSV-2 strains has not been extensively 
studied, although (Liljeqvist et al., 2000) found a gG-2 epitope, as determined by using a 
monoclonal antibody, to be highly conserved among 2,400 HSV-2 isolates, these isolate were 
all from northern Europe, and no studies have evaluated the relatedness of HSV-2 isolated in 
Africa. Recently, we focused on DNA sequencing analysis of the glycoproteins G (gG-2), and 
in addition on genes encoding gI-2 and gE-2 to add the number of sequences available for 
phylogenetic comparison.  
 
3.4 Aetiology of genital ulcers among patients attending STD clinic in Tanzania 
 
Although it is generally recognized that sexually transmitted infections (STIs), particularly 
those causing genital ulceration, facilitate HIV transmission (Mbopi-Keou et al., 2002; 
Celum, 2004), and HIV infection may simultaneously prolong or augment the infectiousness 
of individual with (STIs), yet little information exist on the causative agents of genital 
ulceration among STD patients in Tanzania. Four infectious agents have so far been identified 
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as common causes of GUD: herpes simplex virus type 2 (HSV-2), HSV-1, Treponema 
pallidum, which is known to cause syphilis, and Haemophilus ducreyi, which causes 
chancroid. Currently, the diagnosis of GUD in many African countries is based primarily on 
the clinical presentation of the ulcer. Since clinical diagnosis of GUD is difficult due to the 
diversity of clinical manifestations of genital herpes, and occurrence of multiple and mixed 
infections, we have analysed material from genital ulcers to identify the causative agent(s) 
which could help in designing appropriate control measures of STDs including HIV infection.  
 
4.0 Aims of the study 
 
• To evaluate the performances of three synthetic branched oligopeptides for specific 
      detection of HSV-1 antibodies (Paper 1).  
 
• To use the newly established method, as well as other ones, to determine acquisition 
patterns of HSV-1 and HSV-2 infection among Tanzanian children and young persons 
aged 1 to 20 years old (Paper 2). 
 
• To investigate genetic variability of clinical HSV-2 isolates from Dar es Salaam, 
Tanzania and Bergen, Norway and to compare the strains from each region (Paper 3). 
 
• To analyse material from genital ulcers to determine which proportion is caused by 














5.0 Summary of results 
Paper I 
 
This paper describes an evaluation of an enzyme-immunoassay for detection of herpes 
simplex virus type 1 (HSV-1) glycoprotein G (gG-1)-specific antibodies in human sera. The 
assay is based on a 16mer peptide (presented as branched tetramer) representing an 
immunodominant sequential region of glycoprotein G of HSV-1. The selection process 
involved a core peptide to march an immunodominat region of gG-1. One N-terminally and 
one C-terminally elongated peptide were also tested for suitability. Sera grouped into four 
classes according to their results with a commercial HSV immunoblot using recombinantly 
expressed gG-1 and gG-2 were tested with the peptide assay. Furthermore, the peptide assay 
results were compared with results obtained by an immunoassay using recombinant gG-1. 
The results show that no differences were found between the peptide corresponded in 
sequence to the immunodominant region and the assay with recombinant antigen. This 
findings suggests that the peptide corresponded in sequence to the immunodominant region 




In this work we took advantage of the findings described in paper I and used the newly 
established HSV-1 peptide-ELISA as well as other ones to investigate the prevalence of 
specific HSV antibodies. To approach this problem, sera were collected from Tanzanian 
children and young people aged 1 to 20 years old and thereafter divided into five different age 
groups using intervals of 4 years with at least 100 individuals in each age group. Sera were 
analyzed by using the WB-UB method which has shown to perform well in comparison with 
a commercial Western blot assay as well as peptide-ELISA methods for specific detection of 
HSV antibodies. Due to strong correlation between HIV and HSV-2 (Celum, 2004), all sera 
were also analyzed in the laboratory of Bionor for the detection of HIV-1 and HIV-2 
antibodies. Our results show that HSV-1 infections occur early in life in Tanzania, as 74% of 
the individuals aged 2 to 4years old had specific antibodies, and more than 80% of children in 
the age group of 5 to 8 years had specific antibodies. The prevalence of HSV-2 antibodies was 
surprisingly high, as 15% of the children were infected at an age of 8 years, with an increase 
to 40% for the age group of 17 to 20 years old, suggesting that non-sexual transmission of 
HSV-2 is common than previously thought. No statistical significant association between 





Genetic diversity among herpes simplex virus type 2 (HSV-2) is of potential importance for 
diagnostics and vaccine development. However, little is known. In the present work, we have 
sequenced gene segment coding for gG, gI and gE as well as the non-coding region between g 
I and gE from 11 Tanzanian isolates and 10 Norwegian isolates. The sequences were 
compared to the reference HSV-2 strain HG52. Overall, sequence variation was low, with an 
overall similarity between the two most distant isolates of 99.6%. Phylogenetic analysis 
revealed that HSV-2 strains are classified into two genogroups, designated Africa (A) and 
European (E) supported by high bootstrap values. All strains classified in A genogroup were 
isolated in Tanzania, while the E genogroup contained both Tanzanian and Norwegian strains 
for gI/gE as well as for gG trees. This findings suggests that three clinical HSV-2 isolates 
collected from patients in Tanzania presenting a genetic pattern consistent with homologous 
recombination between the A and E genotypes. Mutations within the epitope regions I and II 
identified by monoclonal antibodies were detected in 2 Norwegian isolates 5 and 7∗. Further 
investigation of possible influence of alteration in gG in diagnosis was beyond the scope of 
the present study, but it forms the bases for future studies. 
 
Paper  IV  
The most common etiologic agents of genital ulcer disease (GUD) are herpes simplex virus 
type 1 (HSV-1), HSV-2, Treponema pallidum, and Haemophilus ducreyi. Genital ulceration 
is recognized as a risk factor for the heterosexual transmission of HIV-1 infection (Rottingen 
et al., 2001). Although a significant association with chancroid and syphilis has been reported 
earlier, there are studies showing that HSV-2 is increasingly associated with HIV-1 infection 
(Mbopi-Keo et al., 2002; Celum, 2004). In an outpatient clinic for sexually transmitted 
diseases in Dar es Salaam, Tanzania, specimen from 301 patients with GUD were collected. 
Of 301 patients recruited into the study, herpes simplex virus type 2 infection was detected in 
64%,  herpes simplex virus type 1 in 5.9%, Haemophilus ducreyi in 3.9% and Treponema 
pallidum in 3.3%. No pathogens were detected in 30% of patients. 6.6% of patients had mixed 
infections. The results show that HSV-2 is the predominant cause of genital ulcers among 
Tanzanian STD patients, and HSV-1 is as least as common as the agents causing syphilis and 
chancroid. 
                                                          
∗ There was originally a printing error here, stating that 5/5 genotype A strains presents with amino acid changes 
within the suggested immunodominant region. This was not consistent with the results in paper III. 
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6.0 General discussion 
 
Peptide ELISA for detection of HSV-1 antibodies 
The ability to discriminate between HSV-1 and HSV-2 infections by using reliable HSV type-
specific serological method is essential for several purposes, including seroepidemiological 
studies, to evaluate the efficacy during trials of HSV prophylactic agents such as potential 
vaccines. An important part of these studies is determination of the frequencies of type-
specific seroconversions. Seroconversion may also be an important parameter in attempts to 
estimate the optimal dosage of antiviral treatment. Although previous evidence suggested that 
the majority of genital herpes infections were HSV-2-related, recent reports suggested an 
increase in HSV-1 genital infection, sometimes outnumbering cases caused by HSV-2, 
especially in women (Stanberry et al., 1999; Taylor et al., 1999). Development of sensitive, 
specific and reliable diagnostic method is of utmost importance, since HSV-1 and HSV-2 
genital infections are less clearly clinically separate than once was the case.  
 
An initial study of the binding of antibodies to three different HSV-1 peptides (paper I) were 
performed in order to select the peptide which was most specific and sensitive in the ELISA 
format. Our results indicate that the peptide corresponding in sequence to the 
immunodominant region in gG-1 (peptide 2048.8) was suitable for the specific detection of 
serum antibodies to HSV-1. However, when analyzing sera from young children (paper II), 
this ELISA was less sensitive and specific than was peptide 55 ELISA for specific detection 
of HSV-2 antibodies. The reasons are not clear. One explanation could be that the peptide 
used did not mimic the epitope as well as peptide 55 mimics the HSV-2 epitope. Furthermore, 
it is not known why addition of three flanking amino acids to either end of the peptide 
reduced both the specificity and the sensitivity. It would have been interesting to investigate 
whether reducing the number of amino acids in the peptide might help to improve the 
performance of the assay. However, it was beyond the scope of this study to investigate the 
effects of such modifications. African sera are known to produce a high degree of false 
positive results regardless of the method used for analysis of antibodies (Hogrefe et al., 2002). 
Could it be due to amino acid differences in gG, since many assays in which gG is used as 
antigen are based on isolates from Europe and America. However, in our study (paper I) 
comparable results were obtained for Scandinavian and African sera when analyzing them 
with peptide HSV-1 ELISA, commercial ELISA kit and a commercial immunoblot kit for 
Scandinavian and African sera.  
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Detection of HSV specific antibodies 
 
Herpes simplex virus type 1 (HSV-1) is transmitted by close contact through mucosas in the 
oro-pharyngeal region. In contrast, the vast majority of infections with herpes simplex virus 
type (HSV-2) are transmitted sexually. The seroprevalence of HSV-2 antibodies in adults has 
been studied in several places in the world and shown to vary by country and group of 
population.  Reports from the African continent indicate that the percentage of HSV-2 
infected adults has increased in recent years. This is alarming, when considering the 
association between infection with HSV-2 and HIV as mentioned earlier.  
 
Little is known about HSV-2 infections in Africa in childhood and adolescence. Although 
most HSV-1 infections are acquired in childhood, very few studies from Africa have focused 
on the pattern and time of acquisition, as we did in paper II. In addition, we wanted to 
investigate the performances of the two newly developed ELISA methods for specific 
detection of HSV-1 and HSV-2 antibodies. To study the acquisition pattern of HSV 
infections, we analyzed more than 500 sera from children and young people aged 1 to 20 
years using methods that discriminate between HSV-1 and HSV-2 antibodies. The methods 
were an in-house Western blot designated WB-UB which was evaluated against a commercial 
Western blot, and two ELISA methods in which the antigenic oligopeptides were specific for 
either HSV-1 or HSV-2 (Kasubi et al., 2005; Marsden et al., 1998). Due to a strong 
correlation between infections of HSV-2 and HIV, all sera were also screened for HIV 
antibodies.   
 
The work described in paper II show that prevalence of HSV-1 antibodies was more than 70% 
in the age group 1-4 years old, increasing to about 90% in the age group 17-20 years, 
indicating that HSV-1 infections occurs early in life in Tanzania compared to similar studies 
conducted in Sweden and Germany (Tunbäck et al., 2003; Wutzler et al., 2000). About 20% 
in age group 1-4 years had HSV-2 antibodies. The detected antibodies in this age group could 
include maternal antibodies, since the figures decreased to 14% in age group 5-8 years. 
Thereafter the HSV-2 prevalence increased continuously to reach 40% in the age group 17-20 
years. The high percentage of HSV-2 infection in children and young people was unexpected, 
suggesting that non-sexual means of HSV-2 spread might play a major role of HSV-2 
transmission in young children. The present work did not investigate how non-sexual means 
of HSV-2 spread might occur. One possibility is through contaminated fingers.  Recently, 
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haematogenous vertical transmission of HSV-1 has been described in mice (Burgos et al., 
2006). However, it is not clear whether similar mode of transmission would be possible in 
human. The idea of non-sexual transmission of HSV-2 has also been suggested earlier by 
other investigators (Löwhagen et al., 2002).  
 
Statistically, no significant association between HSV-2 and HIV was observed (paper II), 
although other investigators have demonstrated such association in adult cohorts. This 
difference could possibly be explained by the probability that relatively more children had 
congenital HIV infections than had sexually active adult.  
 
Ashley, (2001), as well as manufacturers of commercial kits, have reported difficulties in 
interpretation of results when analyzing sera from persons younger than 14 years old for the 
presence of HSV specific antibodies. Similar findings have been reported in the present work, 
except that the problems seem to be more limited to sera from young children (paper II). The 
reason is unknown. However, one explanation might be that the patterns of immunoglobulins 
are different in sera from children and from adults. Specifically, textbooks in immunology 
indicate that the level of IgG in younger age group could be relatively low, and then increases 
with age. Consequently, the ratio between antibodies directed to a specific pathogen, and the 
total amount of immunoglobulins, could be different from the ratio later in life. In addition, 
the amount of IgM could possibly play a role, because it is the most efficient immunoglobulin 
in agglutination. At the age of one year, the infant produces 75% of what is the adult IgM 
level, thereafter the IgM level increases with age.  
 
Genetic diversity of gG-2, gE-2 and gI-2 
 
The identification of extensive sequence diversity and the presence of multiple HSV-2 
subtypes co circulating within a defined population may be of importance for the design and 
application of effective vaccines. In addition, divergent isolates may escape detection by 
currently available screening assays. Due to a strong associations between HSV-2 and HIV, 
identification and characterization of divergent HSV-2 isolates is important with respect to 
evaluation and possible modification of diagnostic assays in the future, and for development 
of effective vaccines. However, our knowledge in this area is still very limited. The results in 
paper III shows that the HSV-2 isolates from Tanzania and Norway had genetic similarity of 
approximately 99.6%. Similar findings of conserved genetics have been reported by other 
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investigators for HSV-1 and VZV (Norberg et al., 2004; Loparev et al., 2004). The conserved 
genetics of clinical HSV-2 isolates from the two regions probably reflects the low mutation 
rate in herpes viruses compared to RNA viruses such as HCV (Kato et al., 1994).  
 
Although a small number of HSV-2 isolates were studied, and despite their genetic similarity, 
two phylogenetically distinct groups were clearly detected and designated European (E) and 
African (A). The laboratory strain HG52 was included as reference. The sequences in the two 
groups were geographically separated. However, exception to this were the Tz_2032, 
Tz_1855 and Tz_2737 sequences which clustered in group A in one phylogenetic tree and in 
group E in the other tree. We concluded (paper III) that these three isolates might represent 
recombination events between African and European genotypes indicating that Dar es Salaam 
city is populated with a mixture of strains. The process of recombination is important for 
generating diversity and genome stability, as it is essential for repair of some types of DNA 
lesions (Yao and Elias, 2001). It would have been interesting to study larger numbers of 
isolates both from Norway and from Tanzania.  
 
Aetiology of genital ulcer diseases 
 
Several seroprevalence studies of HSV-2 and syphilis have been conducted in Tanzania 
among individuals at high risk of STI (Langeland et al., 1998; Mwansasu et al., 2002; Nilsen 
et al., 2005). However, a smaller number of studies have been conducted to investigate the 
specific aetiology of GUD among patients attending STD clinics. 
 
Laboratory diagnosis of GUD is not done routinely in Tanzania due to lack of the necessary 
laboratories or facilities and experienced personnel. Hence, in many areas of Tanzania the 
diagnosis of GUD is based on clinical appraisal. Reports on the most common causative 
agents in given areas are limited. The use of PCR has improved the diagnosis of GUD. 
Previously, the detection of some of the causative agents required Gram staining and/or 
culture which are less accurate and sensitive procedures (Dangor et al 1990). The advantage 
of PCR include the ability to transport samples off-site for testing as well as its increased 
sensitivity relative to culture, presumably due to the difficulties in growing fastidious 
organism (Morse et la., 1997; Orle et al., 1996). Most of the genital ulcers were caused by 
HSV-2 in our studied population (paper IV). This findings is in agreement with a previous 
study done in Dar es Salaam, Tanzania, where HSV-2 DNA was detected in 64% of patients 
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with GUD (Mwansasu et al., 2002) and much higher than that reported in a recent study in 
Mbeya region, Tanzania, among female bar and hotel workers where a prevalence of 13.5% in 
52 women with GUD was reported (Reidner et al., 2003). These findings in Tanzania support 
the conclusion that HSV-2 is the leading cause of GUD worldwide (Celum et al., 2004) and 
that HSV-2 infection is common in our studied population. One possible reason for this is that 
efficient syndromic treatment has been targeted to bacterial but not viral genital infections. 
Improved microbiological diagnostic methods for identification of single pathogens, 
particularly HSV, might also have played a role in the apparent increase in prevalence of 
these pathogens. Although the numbers for the other pathogens are small, HSV-1 was 
apparently at least as important as H. ducreyi and T. pallidum.  
 
No pathogen was detected in 30% of the ulcer specimens (paper IV). These ulcers may have 
been caused by other unrecognized ulcerative diseases such as lymphogranuloma venerum or 
granuloma inguinale, which were not examined for, or by sexual trauma. Alternatively lack of 
serous fluid in the ulcers, inadequate specimen collection, and improper storage may have 
occurred. Furthermore, the duration of the ulcers might influence the probability of detecting 
the causative agent. Similar findings have been documented by other investigators, who have 
used multiplex PCR. In a study done in the Netherlands, 37% of ulcer specimens were 
negative (Bruisten et al 2001), 32% in a study done in Atananarivo, Madagascar (Behets et 

















Data from this thesis shows that: 
• A branched, synthetic oligopeptide has been used successfully as antigen for specific 
detection of HSV-1 antibodies. The peptide contained exclusively type-specific-
epitopes identified in gG-1, and displayed no cross-reactivity when 16 HSV-1 
negative/HSV-2 positive sera were analysed in our initial study (paper I). Thus, this 
peptide has the potential to be another antigen for the detection of type-specific human 
anti-gG-1 antibodies.  
 
• HSV-1 infections occurs early in life in Tanzania. The high percentage of HSV-2 
infection especially in young children is a cause of great concern and suggest that non-
sexual means of HSV-2 transmission is more common than expected. Although the 
peptide-ELISA methods for detection of HSV-1 or HSV-2 antibodies performed well, 
their sensitivities and specificities were reduced when analysing sera from children. 
 
• HSV-2 isolates from Tanzania and Norway seemed to be divided in two genetic 
variants designated A (Africa) and E (European), as shown by phylogenetic trees 
based on the sequences of the genes encoding gG-2, gI-2 and gE-2. By comparing the 
trees obtained from the different genes, evidence of recombination events between the 
two genetic variants was found. 
 
• HSV-2 is becoming the most important cause of GUD in Tanzania as in other African 
countries. These results suggest the need for integrating HSV-2 treatment in the 
syndromic management of GUD in Tanzania. Treatment of STI including HSV-2 
could also play a role in preventing HIV infection, and it should be used together with 
other approaches, such as promotion of condom use and behaviour change 
intervention. Currently, some programs for HIV treatment in Africa include antiviral 







8.0 Future perspectives 
 
• Since addition of amino acids to either C-terminal or N-terminal ends of the peptide 
reduced both the sensitivity and specificity of the assay, it would be interesting to 
investigate the functional implication of the antibody binding to peptides containing 
reduced numbers of amino acids. 
 
• Although our study suggested the possibility of non-sexual transmission of HSV-2, we 
could not explain the mechanisms of such transmission. Further studies into the 
possible non-sexual routes of HSV-2 transmission are warranted. 
 
• Given the limited number of clinical HSV-2 isolates collected from each country, that 
the Tanzania isolates were all from Dar es Salaam and only smaller portions of the 
genome were sequenced, this findings should be interpreted with some caution. To 
obtain more firm conclusions, it would have been useful to collect clinical HSV-2 
isolates from the rural areas of Tanzania to be sure that the HSV-2 isolates represented 
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